公开(公告)号：US20180322241A1

公开(公告)日：2018-11-08

申请号：US16038592

申请日：2018-07-18

Applicant: Charles L. Buchanan

Inventor： Charles L. Buchanan

IPC: G06F19/12 ,  G06N3/063 ,  G06N3/08 ,  G06F19/24

CPC classification number: G06F19/18 ,  C40B30/02 ,  G06F19/12 ,  G06F19/24 ,  G06N3/0635 ,  G06N3/084

Abstract: An organism development system includes: at least one neuromorphic device including multiple sets of hardware components that each store one or parameters of neuromorphic configuration data to implement a neuron of a neural network, wherein: the neural network is configured by neuromorphic configuration data to derive a proposed genome or epigenome of a new organism meant to have a sought-for trait, and the neuromorphic configuration data is generated by training the neural network with a usage data set that includes trait data indicative of a trait and biological data indicative of a genome for each of multiple organisms; a genome or epigenome printing device to print genetic/epigenetic material of the new organism based on the proposed genome or epigenome, respectively; and a trait detection device to detect an observed trait of the new organism following its at least its generation for incorporation back into the usage data set.

公开(公告)号：US20180312999A1

公开(公告)日：2018-11-01

申请号：US15769446

申请日：2016-10-19

Applicant: GEORGETOWN UNIVERSITY

Inventor： Salim Shah ,  Qingliang Li

IPC: C40B30/02

CPC classification number: C40B30/02

Abstract: Provided herein are methods of computer-assisted identification of a compound that binds to a target protein.

公开(公告)号：US20180307796A1

公开(公告)日：2018-10-25

申请号：US15957622

申请日：2018-04-19

Applicant: Illumina, Inc.

Inventor： Tingting Jiang ,  Chen Zhao ,  Han-Yu Chuang

IPC: G06F19/24 ,  G06F19/18 ,  G06N3/12 ,  G06N3/04

CPC classification number: G06F19/24 ,  C40B30/02 ,  C40B50/02 ,  G06F19/18 ,  G06F19/22 ,  G06N3/0472 ,  G06N3/126

Abstract: Methods and systems are provided for determining a variant of interest by analyzing sizes and sequences of cfDNA fragments obtained from a test sample. The methods and systems provided herein implement processes that synergistically combine size and sequence information, thereby improving specificity and sensitivity of assays over conventional methods.

公开(公告)号：US20180244722A1

公开(公告)日：2018-08-30

申请号：US15965212

申请日：2018-04-27

Applicant: immatics biotechnologies GmbH

Inventor： Juliane STICKEL ,  Daniel Johannes KOWALEWSKI ,  Hans-Georg RAMMENSEE ,  Stefan STEVANOVIC

IPC: C07K7/06 ,  A61K39/00 ,  G01N33/574 ,  C12Q1/6886 ,  C12N5/0783 ,  C40B30/02 ,  C07K14/74 ,  C07K14/47

CPC classification number: C07K7/06 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/585 ,  C07K14/4748 ,  C07K14/70539 ,  C12N5/0638 ,  C12N2501/998 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C40B30/02 ,  G01N33/574 ,  G01N2333/70539

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

公开(公告)号：US09890434B2

公开(公告)日：2018-02-13

申请号：US14662220

申请日：2015-03-18

Applicant: NATIONAL TSING HUA UNIVERSITY

Inventor： Wen-Ching Wang ,  Hsing-Jien Kung ,  Chia-Han Chu ,  Jing-Moon Yang

IPC: C12Q1/26 ,  C40B30/02 ,  G06F19/16

CPC classification number: C12Y114/11027 ,  C12Q1/26 ,  C40B30/02 ,  G01N2333/90245 ,  G01N2500/04 ,  G06F19/16

Abstract: The present invention relates to a method for identifying a compound that inhibits an activity of a histone lysine demethylase.

公开(公告)号：US09842198B2

公开(公告)日：2017-12-12

申请号：US14405415

申请日：2013-06-05

Applicant: McMaster University

Inventor： Nathan Magarvey ,  Aubrey Bailey Morgan Wyatt ,  Chad William Johnston ,  Ashraf Ibrahim ,  Bin Ma ,  Lian Yang

IPC: G01N33/48 ,  G01N33/50 ,  G06F19/00 ,  G01N33/68 ,  C40B30/02 ,  G06F19/16 ,  G06F19/18 ,  C40B20/08 ,  G01N30/86 ,  G01N30/72

CPC classification number: G06F19/703 ,  C40B20/08 ,  C40B30/02 ,  G01N30/7233 ,  G01N30/86 ,  G01N33/6848 ,  G06F19/16 ,  G06F19/18

Abstract: The present application is directed to methods and systems for identifying small molecule compounds in mixtures using a library comprising calculated structures and corresponding calculated mass spectral fragmentation patterns of known and/or hypothetical small molecule compounds that may be in the mixture and screening of a mass spectrum of the mixture using the library to identify matching fragmentation patterns. If a mass spectral fragmentation pattern present in the mass spectrum of the mixture matches a calculated fragmentation pattern of one of the known or hypothetical compounds this confirms the identity of a compound in the mixture as the known or hypothetical compound. The method represents a platform method that can be used for a multitude of purposes related to the screening and identification of compounds in mixtures. Therefore the methods and systems of the present application represent an approach that is uniquely capable of navigating chemical space and providing a understanding of desired families and pharmacophores.

公开(公告)号：US20170248601A1

公开(公告)日：2017-08-31

申请号：US15442639

申请日：2017-02-25

Applicant: Massachusetts Institute of Technology

Inventor： Thomas U. Schwartz ,  F. Esra Demircioglu ,  Brian A. Sosa-Alvarado

IPC: G01N33/573 ,  C40B30/02 ,  G06F19/16 ,  G06F19/18 ,  C12N9/14 ,  G01N23/20

CPC classification number: G01N33/573 ,  C12N9/14 ,  C12Y306/04 ,  C40B30/02 ,  G01N23/20 ,  G01N2333/914 ,  G01N2500/04 ,  G06F19/16 ,  G06F19/18

Abstract: A protein composition including TorsinA or TorsinA mutant, LULL1, and a nanobody obtained by immunization using TorsinA and LULL1 is used to grow complex crystals, and three dimensional structures are determined using x-ray data of the crystals. A creening platform is built based on the determined three dimensional structures for designing a drug lead to cure dystonia.

公开(公告)号：US09731001B2

公开(公告)日：2017-08-15

申请号：US14367741

申请日：2012-12-20

Applicant: Universite Laval

Inventor： Caroline Gilbert ,  Michel J. Tremblay ,  Sheng-Xiang Lin ,  Arezki Azzi ,  Alexandra Lambert

IPC: A61K31/40 ,  A61K31/34 ,  A61K31/13 ,  A61K39/21 ,  A61K31/12 ,  A61K31/343 ,  A61K31/352 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/501 ,  A61K31/655 ,  C40B30/02 ,  C07K14/705 ,  C07C49/796 ,  C07C291/08 ,  C07D215/58 ,  C07D257/04 ,  C07D271/12 ,  C07D277/64 ,  C07D307/79 ,  C07D307/80 ,  C07D311/82 ,  C07D401/04 ,  C07D401/14 ,  C07D405/06 ,  C07D417/14

CPC classification number: A61K39/21 ,  A61K31/12 ,  A61K31/343 ,  A61K31/352 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/501 ,  A61K31/655 ,  C07C49/796 ,  C07C291/08 ,  C07D215/58 ,  C07D257/04 ,  C07D271/12 ,  C07D277/64 ,  C07D307/79 ,  C07D307/80 ,  C07D311/82 ,  C07D401/04 ,  C07D401/14 ,  C07D405/06 ,  C07D417/14 ,  C07K14/7056 ,  C40B30/02

Abstract: The invention is concerned with compounds, pharmaceutical compositions, screening methods, and therapeutic methods for preventing or reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or propagation associated with dendritic cell immunoreceptor (DCIR). Described herein are compounds which bind on at least one three-dimensional cavity of the DCIR, the cavity(ies) being involved in the interaction between HIV-1 and DCIR. Also described are screening methods for identifying active inhibitors and method of using such inhibitors for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus type-1 (HIV-1) binding, entry and/or replication in human cells.

公开(公告)号：US09720000B2

公开(公告)日：2017-08-01

申请号：US14713721

申请日：2015-05-15

Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

Inventor： Sathibalan Ponniah ,  George E Peoples ,  Catherine E Storrer ,  Michael Flora

IPC: G01N33/53 ,  G01N33/68 ,  A61K39/00 ,  G01N33/50 ,  G01N33/564 ,  G01N33/574 ,  A61K39/395 ,  C07K16/32 ,  C40B30/02 ,  G01N33/577

CPC classification number: G01N33/6803 ,  A61K39/0011 ,  A61K39/39558 ,  C07K16/32 ,  C40B30/02 ,  G01N33/5011 ,  G01N33/564 ,  G01N33/574 ,  G01N33/577 ,  G01N33/6845 ,  G01N2500/00 ,  G01N2500/04 ,  A61K2300/00

Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.

公开(公告)号：US09718859B2

公开(公告)日：2017-08-01

申请号：US14392205

申请日：2014-06-24

Applicant: Ramot at Tel-Aviv University Ltd. ,  Yeda Research and Development Co. Ltd.

Inventor： Hagit Eldar-Finkelman ,  Miriam Eisenstein ,  Avital Licht-Murava

IPC: A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  A61K47/48 ,  C40B30/02 ,  G06F19/16 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  C07K7/08 ,  C40B30/02 ,  G06F19/16 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/419 ,  Y02A50/422 ,  Y02A50/423 ,  Y02A50/491

Abstract: Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are converted to inhibitors of GSK-3 upon interacting with the enzyme's catalytic site and hence act as disease-selective inhibitors for treating conditions associated with increased activity and/or expression of GSK-3. Each of the disclosed peptides is independently of no more than 15 amino acid residues, and has an amino acid sequence which comprises a ZX1X2X3Z(p) recognition motif of GSK-3, wherein Z(p) is a phosphorylated serine or threonine residue; Z is a phosphorylatable serine or threonine residue, and each of X1, X2 and X3 is independently any amino acid, as defined in the specification. Further disclosed are methods of identifying a putative substrate-competitive peptide inhibitor of GSK-3 which are effected by computational modeling and screening.